Sunshine Biopharma Sets Reverse Split to Hold Nasdaq Listing
SBFM is trading near its 52-week low of $0.186 (12% below the low) on light trading volume (0.1× avg).
Summary
Sunshine Biopharma is going ahead with a reverse stock split to keep its Nasdaq listing, following the CEO's written consent in the September 16 8-K authorizing a split of up to 1-for-20 and the October 14 consent covering the share combination. The move comes after a $6M unit offering at $0.55 per unit on October 9 that added Series D warrants potentially worth up to 43.6M shares, and a stock that has collapsed from a 52-week high of $23.20 to about $0.16. A reverse split mechanically lifts the share price above Nasdaq's $1 minimum bid but does nothing for the underlying business, and the Series D exercise price can drop to $0.275 after a share combination, so warrant dilution risk stays in place. This is the second reverse split in under five months — a 1-for-10 took effect June 1 — which tells you the listing problem keeps recurring. Watch whether the split ratio and effective date are confirmed in the coming days and whether the bid holds above $1 afterward.
At the time of this announcement, SBFM was trading at $0.16 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $928.4K. The 52-week trading range was $0.19 to $23.20. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Seeking Alpha.